brand logo

Family physicians should be familiar with the various drugs available for treating and preventing viral infections. Part II of this two-part article focuses on agents used to manage influenza and respiratory syncytial virus. Rimantadine and amantadine traditionally have been used to prevent and treat influenza type A infections. The neuraminidase inhibitors zanamivir and oseltamivir have a broadened spectrum of activity in the treatment and prevention of influenza types A and B. Ribavirin has been used in some high-risk infants to treat respiratory syncytial virus infections, and palivizumab can be used for prophylaxis.

RNA viruses generally are benign in the early stage of infection, but they have the potential to induce acute respiratory distress syndrome if they spread to the lower respiratory tract or progress to pneumonia. Antiviral drugs can be used to treat and prevent these infections, although they are not a substitute for vaccine. Part II of this article focuses on antiviral agents used in the management of influenza and respiratory syncytial virus (RSV).

Influenza Viruses

Antiviral drugs that prevent and treat influenza should be considered adjuncts to vaccine—not substitutes. Traditionally, amantadine (Symmetrel) and, to a lesser extent, rimantadine (Flumadine) have been used for preventing and treating influenza type A (Table 1).14 However, in 1999, two drugs that effectively treat and prevent influenza types A and B were introduced. These drugs, zanamivir (Relenza) and oseltamivir (Tamiflu), provide more complete coverage when the type of influenza is unknown (Table 2).14

Drug factorsAmantadine (Symmetrel)Rimantadine (Flumadine)
Generic availabilityYesYes
Dosage formsLiquid and tabletLiquid and tablet
Treatment and prevention of influenza type A in adultsYesYes
Treatment of influenza type A in childrenYesNot approved
Prevention of influenza type A in childrenYesYes
Dosages for treatment of influenza type AAdults* and children 12 years of age: 200 mg daily until 24 to 48 hours after symptoms have disappearedAdults* and children 10 years of age: 100 mg twice daily for seven days
orNot approved for children < 10 years of age
100 mg twice daily† until 24 to 48 hours after symptoms have disappeared
Children one to nine years of age: 5 mg per kg daily (up to 150 mg daily) until 24 to 48 hours after symptoms have disappeared
Children 10 to 11 years of age: 100 mg twice daily until 24 to 48 hours after symptoms have disappeared
Dosages for prevention of influenza A‡Adults* and children 12 years of age: 200 mg daily for at least seven daysAdults* and children 10 years of age: 100 mg twice daily for at least seven days
or
100 mg twice daily for at least seven daysChildren < 10 years of age: 5 mg per kg daily (up to 150 mg daily) for at least seven days
Children one to nine years of age: 5 mg per kg daily (up to 150 mg daily) for at least seven days
Children 10 to 11 years of age: 100 mg twice daily for at least seven days
Prevention and treatment of influenza BNoNo
Dosage reduction in renal impairmentYes (creatinine clearance 50 mL per minute [0.83 mL per second])Yes (creatinine clearance 10 mL per min [0.17 mL per second])
Side effectsCNS and GIPrimarily GI
Cost (generic)§
Five-day treatment (adult dosage)$18 ($4 to $5)$29 ($26)
42-day treatment (adult dosage in community outbreaks)$106 ($28 to $31)$171 ($154)
Drug factorsOseltamivir (Tamiflu)Zanamivir (Relenza)
Generic availabilityNoNo
Dosage formsLiquid and capsulePowder for oral inhalation
Treatment of influenza types A and B in adultsYesYes
Treatment of influenza types A and B in childrenYes, in children > one year of ageYes, in children seven years of age
Prevention of influenza types A and B in adultsYesFDA approval pending
Prevention of influenza types A and B in childrenYes, in children 13 years of ageFDA approval pending
Dosage for treatment of influenza types A and B*Adults and children 13 years: 75 mg twice daily for five daysTwo inhalations (10 mg) twice daily for five days
Children one to 12 years (following doses are given twice daily for five days):
15 kg (33 lb) or less: 30 mg
15 kg to 23 kg (51 lb): 45 mg
23 kg to 40 kg (88 lb): 60 mg
> 40 kg: 75 mg
Dosage for prevention of influenza types A and BAdults and children 13 years: 75 mg once daily for at least seven days†Approval pending. Two inhalations (10 mg) once daily for at least seven days†
Dosage reduction in renal impairmentYes (creatinine clearance 30 mL per minute [0.5 mL per second])No
Side effectsGIMinimal
Cost‡
Five-day treatment (adult dosage)$63$50
42-day treatment (adult dosage in community outbreaks)$265$212 (approval pending)
PrecautionsTake with food to improve toleranceNot recommended in patients with asthma or COPD
Suspension should be shaken before each use and is stable at room temperature for 10 days
May cause bronchospasm

INFLUENZA TYPE A

Amantadine and Rimantadine

Amantadine was the first drug approved for prophylaxis of influenza type A (in 1966), and in 1976, it was approved for treatment and prophylaxis in adults and children older than one year. Rimantadine became available in 1993 for treatment and prophylaxis of influenza type A in adults and for prophylaxis in children. Neither of these drugs is effective against influenza type B.

Treatment usually is continued for three to five days or discontinued 24 to 48 hours following resolution of symptoms. The efficacy of both drugs is similar, and the average duration of illness is shortened by approximately one day.5

These drugs can be used for prophylaxis in high-risk patients (Table 3)6 and for influenza-related complications if an outbreak of influenza occurs within two weeks following vaccination.4 In a recent review, the average effectiveness of amantadine and rimantadine for the prevention of influenza was 61 and 72 percent, respectively.7

The rightsholder did not grant rights to reproduce this item in electronic media. For the missing item, see the original print version of this publication.

Although amantadine is considerably less expensive than rimantadine, it crosses the blood-brain barrier and appears to cause more central nervous system side effects, including dizziness, ataxia, hallucinations, agitation, and confusion. This is especially true in elderly patients and may be associated with higher serum concentrations. A split dosage may help minimize adverse events.

Amantadine is primarily eliminated in the kidneys as unchanged drug; therefore, the dosage must be modified in elderly patients and patients with reduced renal function (Table 4).8

Creatinine clearance, mL per minute (mL per second)Suggested maintenance regimen
30 to 50 (0.5 to 0.83)100 mg daily*
15 to 29 (0.25 to 0.48)100 mg every other day*
< 15 (0.25)200 mg every seven days

Rimantadine's adverse drug-reaction profile is similar to that of amantadine with respect to gastrointestinal side effects such as nausea, vomiting, and dyspepsia, but rimantadine appears to cause fewer central nervous system side effects.9

Oseltamivir and Zanamivir

Oseltamivir, which is taken orally, was approved for prophylaxis of influenza in late 2000, and zanamivir's approval for prophylaxis is pending. They are equally effective in reducing symptoms and duration of illness when taken within 48 hours of the onset of symptoms.1014

Zanamivir is inhaled and requires the use of an inhalation device, which may be difficult for elderly patients to use. Because of its potential to induce bronchospasm and reduce lung function, use of zanamivir generally should be avoided in patients with asthma and chronic obstructive pulmonary disease.

INFLUENZA TYPE B

Oseltamivir and zanamivir are first-line choices for prevention and treatment of infection during outbreaks of influenza type B.

Respiratory Syncytial Virus (RSV)

RSV is a frequent cause of bronchiolitis in children. Treatment consists primarily of supportive care with fluids, oxygen, and aerosolized bronchodilators.

Ribavirin

In a select group of high-risk infants (premature infants younger than 36 weeks and infants with bronchopulmonary dysplasia, congenital heart disease, or immunodeficiency) with severe infections, aerosolized ribavirin (Virazole) has been used.15 The use of this drug requires special equipment and expert respiratory monitoring. It is expensive, with a cost exceeding $1,000 per day.

RSV Immune Globulin and Palivizumab

In high-risk patients, prophylaxis against RSV should be considered. During the winter months, monthly administration of intravenous RSV immune globulin (RespiGam) or intramuscular palivizumab (Synagis) may decrease the number of RSV episodes. Because of increased morbidity, RSV immune globulin should not be given to patients with congenital heart disease.

Continue Reading


More in AFP

More in PubMed

Copyright © 2003 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.